NCT01775189View on ClinicalTrials.gov

A Study to Characterize the Abuse Liability of ALO-02 in Healthy, Non-Dependent, Recreational Opioid Users When ALO-02 Capsules Are Crushed and Snorted

PHASE1CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

February 28, 2013

Primary Completion Date

July 31, 2013

Study Completion Date

July 31, 2013

Conditions
Healthy
Interventions
DRUG

ALO-02 weight-matched placebo

crushed sugar spheres (powder) x 1 dose

DRUG

crushed ALO-02 30 mg/3.6 mg

crushed ALO-02 30 mg/3.6 mg capsule x 1 dose

DRUG

oxycodone weight-matched placebo

crushed lactose tablets (powder) x 1 dose

DRUG

crushed oxycodone IR 30 mg

Three (3) crushed immediate-release (IR) oxycodone 10 mg tablets x 1 dose

Trial Locations (1)

M5V 2T3

INC Research Toronto Inc., Toronto

Sponsors

Lead Sponsor

Pfizer

Collaborators (1)

Syneos Health
All Listed Sponsors
collaborator

Syneos Health

OTHER

lead

Pfizer

INDUSTRY

NCT01775189 - A Study to Characterize the Abuse Liability of ALO-02 in Healthy, Non-Dependent, Recreational Opioid Users When ALO-02 Capsules Are Crushed and Snorted | Biotech Hunter | Biotech Hunter